Global X Genomics & Biotechn (GNOM) Technical Analysis
$7.66▲2.31%
Market is closed - opens 7 PM, 09 May 2025
Insights
- Global X Genomics & Biotechn is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Global X Genomics & Biotechn stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Global X Genomics & Biotechn stock is Range bound.
- Based on analysis of the Pivot Points, the current market trend for Global X Genomics & Biotechn stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 42.95 | Neutral |
Stochastic | 27.78, 15.6 | Neutral |
Ultimate Oscillator | 45.11 | Neutral |
Stochastic Relative Strength Index | 9.99, 36.66 | Neutral |
Moving Average Convergence Divergence | -0.1, -0.1 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.97 | Buy |
20 | 7.84 | Sell |
50 | 8.24 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.85 | Sell |
20 | 7.91 | Sell |
50 | 8.29 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.8 | Neutral |
20 | 7.73 | Neutral |
50 | 8.17 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.77 | Buy |
20 | 7.76 | Buy |
50 | 7.59 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.68 | Sell |
20 | 7.87 | Buy |
50 | 7.54 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 7.76 |
Resistance L2 | 7.68 |
Resistance L1 | 7.58 |
Pivot Point | 7.5 |
Support L1 | 7.4 |
Support L2 | 7.32 |
Support L3 | 7.22 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.